Susan Breslin

Three-dimensional cell culture: the missing link in drug discovery.

L. O’Driscoll, Susan Breslin, 2013, Drug discovery today.

Neuromedin U: a candidate biomarker and therapeutic target to predict and overcome resistance to HER-tyrosine kinase inhibitors.

L. O’Driscoll, S. Rani, C. Corcoran, 2014, Cancer research.

Resistance to HER2-targeted anti-cancer drugs is associated with immune evasion in cancer cells and their derived extracellular vesicles

L. O’Driscoll, A. Clayton, J. Crown, 2017, Oncoimmunology.

Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4

L. O’Driscoll, Susan Breslin, Michelle C. Lowry, 2017, British Journal of Cancer.

The relevance of using 3D cell cultures, in addition to 2D monolayer cultures, when evaluating breast cancer drug sensitivity and resistance

L. O’Driscoll, Susan Breslin, Lorraine O'Driscoll, 2016, Oncotarget.

Neuromedin U: A Candidate Biomarker and Therapeutic Targetto Predict and Overcome Resistance to HER-Tyrosine

L. O’Driscoll, S. Rani, C. Corcoran, 2015 .

Neratinib

Susan Breslin, Michelle C. Lowry, 2019, Reactions Weekly.

miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer

L. O’Driscoll, S. Rani, C. Corcoran, 2014, Molecular Cancer.